$42.2 M

OGEN Mkt cap, 22-Sept-2020
Oragenics Net income (Q2, 2020)-12.3 M
Oragenics EBIT (Q2, 2020)-12.4 M
Oragenics Cash, 30-Jun-20209.6 M
Oragenics EV33.4 M

Oragenics Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

347.6k350.4k380.5k256.4k176.4k167.7k253.4k214.7k303.8k201.0k363.8k242.0k329.8k262.3k

Cost of goods sold

328.8k134.4k198.2k112.3k63.9k86.7k113.4k79.8k125.6k73.7k168.0k86.8k134.6k90.0k

Gross profit

18.8k215.9k182.3k144.1k112.5k81.0k140.0k134.9k178.1k127.3k195.8k155.3k195.2k172.3k

Gross profit Margin, %

5%62%48%56%64%48%55%63%59%63%54%64%59%66%

R&D expense

631.4k562.7k353.2k6.2m745.4k637.0k6.9m1.0m903.3k597.0k676.6k5.6m1.2m1.2m812.6k924.8k1.1m605.4k996.5k1.3m1.6m2.4m3.9m3.1m3.7m11.5m

General and administrative expense

1.7m1.4m1.3m835.5k1.1m1.5m2.6m767.4k1.2m565.1k815.5k873.6k853.9k994.4k920.7k1.1m865.2k791.3k925.0k1.0m1.2m980.4k1.0m852.8k1.5m808.3k

Operating expense total

2.3m1.9m1.7m7.0m1.8m2.2m9.5m1.8m2.1m1.2m1.5m6.5m2.0m2.2m1.7m2.0m2.0m1.4m1.9m2.3m2.8m3.4m4.9m3.9m5.2m12.4m

EBIT

(2.3m)(1.7m)(1.5m)(6.9m)(1.7m)(2.1m)(9.3m)(1.6m)(1.9m)(1.0m)(1.3m)(6.3m)(1.8m)(2.1m)(1.7m)(2.0m)(2.0m)(1.4m)(1.9m)(2.1m)(2.8m)(3.4m)(4.9m)(3.9m)(5.2m)(12.4m)

EBIT margin, %

(663%)(488%)(389%)(2679%)(984%)(1238%)(3681%)(768%)(626%)(515%)(356%)(2615%)(555%)(787%)

Interest expense

67.7k96.7k138.3k60.1k949.0844.041.08.1k7.0k5.3k3.5k5.2k34.2k647.0280.021.1k5.1k175.8k145.7k2.3k664.06.5k68.5k98.4k83.9k

Interest income

200.0329.0383.01.2k6.4k5.1k3.6k10.8k9.7k8.7k6.6k5.8k5.0k2.6k1.4k18.5k1.9k1.8k3.0k3.5k3.3k9.1k70.1k99.4k86.7k44.5k16.5k

Pre tax profit

(2.4m)(1.8m)(1.6m)(6.9m)(1.6m)(2.1m)(9.3m)(1.6m)(1.9m)(1.0m)(1.3m)(6.3m)(1.9m)(2.1m)(1.7m)(2.0m)(2.0m)(1.2m)(2.1m)(2.1m)(2.3m)(2.8m)(3.3m)(4.8m)(3.8m)(5.2m)(12.3m)

Income tax expense

1.4k(212.0)152.01.1k3.8k3.0k2.0k2.2k1.5k2.0k

Net Income

(2.4m)(1.8m)(1.6m)(6.9m)(1.6m)(2.1m)(9.3m)(1.6m)(1.9m)(1.0m)(1.3m)(6.3m)(1.9m)(2.1m)(312.6k)(2.0m)(2.0m)(1.2m)(2.1m)(2.1m)(2.3m)(2.8m)(3.3m)(4.8m)(3.8m)(5.2m)(12.3m)

Oragenics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

171.7k9.9m16.3m10.4m5.1m4.1m6.2m20.2m18.3m

Accounts Receivable

92.6k69.8k64.4k15.6k21.1k24.1m

Prepaid Expenses

113.3k221.8k175.2k119.4k211.7k1.0m1.7m570.1k

Inventories

475.6k124.2k288.4k439.2k321.5k141.1k

Current Assets

1.1m10.4m16.8m11.0m5.6m4.2m7.2m21.9m18.8m

PP&E

148.7k84.6k26.9k109.3k140.7k87.5k21.7k116.3k92.0k

Total Assets

1.3m10.5m16.8m11.1m5.8m4.3m7.2m22.0m19.8m

Accounts Payable

1.7m1.2m910.0k710.2k969.8k1.3m818.0k1.0m1.5m

Short-term debt

143.9k

Current Liabilities

9.4m1.3m992.8k796.3k1.0m1.3m898.5k1.2m1.9m

Long-term debt

670.7k

Non-Current Liabilities

670.7k

Total Debt

814.6k

Total Liabilities

9.4m

Common Stock

5.9k27.4k36.0k36.2k39.9k4.9k29.4k46.1k

Preferred Stock

6.3m6.1m6.5m

Additional Paid-in Capital

32.8m63.3m86.0m86.2m92.3m97.6m101.4m126.1m138.0m

Retained Earnings

(41.0m)(54.1m)(70.2m)(75.9m)(87.7m)(94.7m)(101.4m)(111.4m)(127.4m)

Total Equity

(8.2m)9.2m15.8m10.3m4.7m3.0m6.3m20.9m17.2m

Financial Leverage

-0.2 x1.1 x1.1 x1.1 x1.2 x1.5 x1.1 x1.1 x1.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

967.9k1.1m11.8m8.4m6.4m8.3m14.6m12.9m11.8m9.1m8.0m6.7m3.4m5.5m5.1m2.2m2.1m2.9m4.8m3.9m13.8m29.3m25.7m22.3m14.4m9.6m

Accounts Receivable

55.1k44.3k63.3k39.4k72.4k55.4k49.6k58.9k42.9k22.8k26.3k29.6k26.8k19.4k32.7k

Prepaid Expenses

168.3k123.9k152.3k236.4k210.5k302.4k227.0k154.4k144.6k221.6k133.8k90.4k173.3k192.9k111.8k171.9k106.3k517.7k769.6k722.6k1.3m1.7m1.7m355.4k555.5k328.7k295.5k

Inventories

500.6k465.5k363.0k353.8k279.9k117.3k303.0k223.3k265.9k239.0k263.9k377.0k364.1k299.3k241.5k

Current Assets

1.1m1.1m1.8m1.9m12.5m8.8m7.0m8.8m15.1m13.3m12.3m9.6m8.5m7.2m3.8m6.0m5.3m2.3m4.5m5.1m5.5m5.2m15.5m31.1m26.1m22.8m14.7m9.9m

PP&E

188.1k168.1k129.1k111.5k92.9k63.6k48.9k38.2k39.3k31.9k26.3k167.7k170.7k159.3k122.4k104.2k107.1k69.4k51.8k34.1k14.0k10.6k63.5k103.6k101.6k89.7k79.7k67.3k

Total Assets

1.3m1.2m1.9m2.0m12.6m8.8m7.1m8.8m15.1m13.3m12.3m9.8m8.7m7.4m4.0m6.1m5.4m2.4m4.6m5.1m5.5m5.2m15.5m31.3m26.9m23.7m15.6m10.7m

Accounts Payable

1.6m1.5m1.3m1.3m1.4m1.1m1.2m2.4m807.4k703.2k604.4k509.3k548.7k761.8k986.7k693.5k786.2k1.1m1.1m1.6m1.1m1.5m1.4m2.0m1.7m1.9m1.8m1.1m

Short-term debt

70.8k302.8k

Current Liabilities

1.8m7.8m1.5m1.4m1.8m1.2m1.4m4.5m938.1k777.9k739.5k606.0k5.6m5.9m1.1m897.8k909.3k1.2m1.1m1.7m1.2m1.6m1.6m2.2m1.9m2.2m2.0m1.4m

Long-term debt

616.2k586.2k627.7k583.9k

Non-Current Liabilities

3.0m2.4m616.2k586.2k627.7k583.9k

Total Debt

616.2k586.2k698.6k886.6k

Total Liabilities

6.3m7.8m

Common Stock

5.7k5.7k12.2k16.6k27.2k27.5k27.5k30.2k36.1k36.2k36.2k36.4k36.4k36.5k40.1k49.1k49.1k49.3k49.3k49.3k5.2k6.1k18.4k46.1k46.1k46.1k46.1k55.4k

Preferred Stock

482.2k1.2m6.1m6.1m6.8m6.5m6.5m6.5m7.2m7.2m

Additional Paid-in Capital

32.3m32.5m42.3m48.1m62.9m63.3m63.4m71.4m86.0m86.2m86.2m86.4m86.6m86.9m92.6m97.2m97.4m97.8m97.8m99.7m101.8m103.4m115.8m137.7m137.8m138.0m138.9m147.1m

Retained Earnings

(37.2m)(39.1m)(42.6m)(49.5m)(52.1m)(55.7m)(57.8m)(67.1m)(71.8m)(73.7m)(74.7m)(77.2m)(83.6m)(85.4m)(89.7m)(90.0m)(92.0m)(96.7m)(97.9m)(99.9m)(103.6m)(105.9m)(108.6m)(115.1m)(119.9m)(123.8m)(133.2m)(145.5m)

Total Equity

(5.0m)(6.6m)(314.3k)(1.4m)10.8m7.6m5.7m4.4m14.2m12.6m11.6m9.2m3.1m1.5m2.9m5.2m4.5m1.2m505.5k1.0m4.3m3.7m14.0m29.1m24.4m20.8m12.9m8.8m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

-0.3 x-0.2 x-6.2 x-1.4 x1.2 x1.2 x1.2 x2 x1.1 x1.1 x1.1 x1.1 x2.8 x4.9 x1.4 x1.2 x1.2 x2 x9.1 x5.1 x1.3 x1.4 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x

Oragenics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.9m)(5.7m)(1.6m)(8.5m)(11.1m)(1.6m)(3.7m)(13.0m)(1.6m)(3.5m)(4.6m)(1.3m)(7.6m)(9.5m)(2.1m)(2.4m)(4.3m)(2.0m)(3.2m)(5.3m)(2.1m)(4.4m)(7.2m)(3.3m)(8.1m)(12.0m)(5.2m)(17.5m)

Depreciation and Amortization

40.1k60.1k19.6k37.2k55.8k21.0k42.1k64.0k6.5k13.3k20.1k13.9k32.5k52.5k18.3k36.5k55.4k18.0k35.7k53.3k7.7k11.0k18.4k12.9k26.2k44.3k13.1k26.0k

Accounts Receivable

67.9k78.6k29.3k53.2k20.3k14.4k20.2k10.9k21.6k41.6k38.1k(14.0k)(11.2k)(3.8k)(11.6k)

Inventories

(233.9k)(198.8k)112.6k121.8k195.6k6.9k61.2k140.9k22.5k49.4k24.5k62.2k75.1k139.9k80.0k

Accounts Payable

96.4k29.0k11.7k1.7k(104.6k)(75.3k)64.9k(280.4k)(102.6k)(206.7k)(305.6k)(200.9k)(161.5k)51.6k17.0k(137.5k)(44.8k)(174.6k)(216.1k)317.2k293.4k719.1k548.5k931.8k697.7k851.4k245.3k(484.2k)

Cash From Operating Activities

(2.6m)(4.1m)(1.1m)(2.3m)(3.5m)(1.6m)(3.6m)(5.5m)(1.6m)(3.3m)(4.4m)(1.3m)(2.2m)(3.5m)(1.7m)(3.5m)(5.1m)(1.9m)(3.7m)(5.0m)(1.4m)(3.6m)(6.1m)(2.2m)(5.7m)(9.1m)(3.8m)(8.7m)

Purchases of PP&E

(6.4k)(17.6k)(18.9k)(18.9k)(20.1k)(72.2k)(93.9k)(102.5k)(27.2k)(60.2k)(11.4k)(11.4k)

Cash From Investing Activities

(6.4k)(17.6k)(18.9k)(18.5k)(19.7k)(72.2k)(93.9k)(101.2k)1.3m1.7m(60.2k)(11.4k)(11.4k)

Short-term Borrowings

(96.8k)(34.4k)(79.0k)(113.5k)(179.4k)(73.0k)(143.9k)

Cash From Financing Activities

2.5m4.0m1.9m3.3m15.1m5.3k29.1k3.9m(34.4k)(79.0k)(113.5k)(34.8k)(79.5k)(113.8k)(33.9k)2.6m3.5m(5.0k)1.7m3.8m(41.6k)1.4m13.8m11.4m11.2m11.2m(73.0k)16.7k

Net Change in Cash

(132.1k)(132.1k)796.2k958.7k11.6m(1.6m)(3.6m)(1.7m)(1.6m)(3.4m)(4.5m)(1.4m)(2.4m)(3.7m)(1.7m)272.3k76.0k(1.9m)(2.0m)(1.2m)(1.4m)(2.2m)7.6m9.1m5.5m2.1m(3.9m)(8.6m)

Interest Paid

3.0k4.3k447.01.3k2.9k982.01.8k3.1k599.01.6k3.0k606.01.5k1.2k771.0885.02.8k801.01.6k3.0k4.5k1.5k3.6k1.3k2.0k4.5k1.7k2.4k

Oragenics Ratios

USDQ2, 2011

Financial Leverage

-0.3 x